The glucagon-like peptide-1 receptor (GLP-1R) and amylin analog pramlintide engage distinct yet complementary structural and functional features that define their protein–ligand interactions and biological efficacy in metabolic disease therapy [70,71]. The gene discussed is GLP1R; the disease is Other metabolic disease.